Mucormycosis after allogeneic haematopoietic stem cell transplantation: A French Multicentre Cohort Study (2003-2008)

Service d'Hématologie- Greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris  Université Paris-Diderot, Sorbonne Cité, Paris  Service des Maladies infectieuses et Tropicales, Centre d'Infectiologie Necker Pasteur, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris  Centre National de Référence Mycologie et Antifongiques, Institut Pasteur, Paris  Département de Bioinformatique Médicale, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris  Unité de Parasitologie-Mycologie, Laboratoire de Microbiologie, HEGP, Assistance Publique-Hôpitaux de Paris, Paris  Service de Pneumologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris  Service d'Hématologie, Centre Hospitalier Universitaire Nancy, Nancy  Service de Parasitologie-Mycologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris  Département d'Oncologie et d'Hématologie, Hôpitaux Universitaires de Strasbourg, Strasbourg  Service d'Hématologie, Centre Hospitalier Universitaire, Besançon,  Service d'Hématologie, Centre Hospitalier Universitaire Nantes, Nantes  Service d'Hématologie, Centre Hospitalier Universitaire Lyon, Lyon  Service d'Hématologie, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, et Université Paris-Est, Créteil  Service d'Hématologie, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris  Service d'Hématologie, Centre Hospitalier Universitaire Saint-Etienne, Saint-Etienne  Service de Pneumologie, Hôpital Foch, Suresnes and  Service d'Hématologie, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.
Clinical Microbiology and Infection (Impact Factor: 5.77). 05/2012; 18(10):E396-E400. DOI: 10.1111/j.1469-0691.2012.03908.x
Source: PubMed

ABSTRACT Clin Microbiol Infect 2012; 18: E396-E400 ABSTRACT: We conducted a nationwide retrospective study to evaluate clinical characteristics and outcome of mucormycosis among allogeneic haematopoietic stem cell transplant recipients. Twenty-nine patients were diagnosed between 2003 and 2008. Mucormycosis occurred at a median of 225 days after allogeneic haematopoietic stem cell transplant, and as a breakthrough infection in 23 cases. Twenty-six patients were receiving steroids, mainly for graft-versus-host disease treatment, while ten had experienced a prior post-transplant invasive fungal infection. Twenty-six patients received an antifungal treatment; surgery was performed in 12. Overall survival was 34% at 3 months and 17% at 1 year.

Download full-text


Available from: Raoul Herbrecht, Jan 21, 2015
6 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mucormycosis is an emerging cause of infectious morbidity and mortality in patients with hematologic malignancies. However, there are no recommendations to guide diagnosis and management. The European Conference on Infections in Leukemia assigned experts in hematology and infectious diseases to develop evidence-based recommendations for the diagnosis and treatment of mucormycosis. The guidelines were developed using the evidence criteria set forth by the American Infectious Diseases Society and the key recommendations are summarized here. In the absence of validated biomarkers, the diagnosis of mucormycosis relies on histology and/or detection of the organism by culture from involved sites with identification of the isolate at the species level (no grading). Antifungal chemotherapy, control of the underlying predisposing condition, and surgery are the cornerstones of management (level A II). Options for first-line chemotherapy of mucormycosis include liposomal amphotericin B and amphotericin B lipid complex (level B II). Posaconazole and combination therapy of liposomal amphotericin B or amphotericin B lipid complex with caspofungin are the options for second line-treatment (level B II). Surgery is recommended for rhinocerebral and skin and soft tissue disease (level A II). Reversal of underlying risk factors (diabetes control, reversal of neutropenia, discontinuation/taper of glucocorticosteroids, reduction of immunosuppressants, discontinuation of deferroxamine) is important in the treatment of mucormycosis (level A II). The duration of antifungal chemotherapy is not defined but guided by the resolution of all associated symptoms and findings (no grading). Maintenance therapy/secondary prophylaxis must be considered in persistently immunocompromised patients (no grading).
    Haematologica 09/2012; 98(4). DOI:10.3324/haematol.2012.065110 · 5.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections are an important cause of morbidity and mortality in hematopoietic stem cell transplant and solid organ transplant recipients. Evolving transplant modalities and techniques, complex and extensive immunosuppressant strategies, and the increased use of broad spectrum antifungal prophylaxis has greatly impacted the epidemiology and temporal pattern of invasive fungal infections in the transplant population. The goal of this article is to provide an up-to-date review of the most commonly encountered invasive fungal infections seen in transplant recipients, including epidemiology, risk factors, clinical features, diagnostic dilemmas, management and their overall influence on outcomes.
    Therapeutic Advances in Infectious Disease 06/2013; 1(3):85-105. DOI:10.1177/2049936113491936
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mucormycosis is a fatal complication in immunocompromised patients, and is additionally difficult to diagnose due to the lack of useful serum biomarkers. Using a quantitative PCR approach, we retrospectively analyzed Mucorales DNA load in sera collected serially from a 3-year-old patient with chronic granulomatous disease, who died of multi-organ failure probably due to dissemination of Rhizomucor pusillus, which was detected from necropsy specimens. Mucorales DNA load was below the detection limit on days 9, 2, and 4 after unrelated bone marrow transplantation. Rhizomucor DNA was first detected on day 14 (1.6 × 10(3) copies/mL), and subsequently fluctuated between 1.3 × 10(3) and 37.2 × 10(3) copies/mL until day 43. Rhizomucor achieved a peak value of 940.0 × 10(3) copies/mL on day 48 the day before death. The detection or fluctuation of Rhizomucor DNA appeared to be associated with corticosteroid dosages or C-reactive protein levels. This specific, noninvasive, and highly quantitative assay may be useful for the early diagnosis of mucormycosis and prediction of disease progression.
    International Journal of Hematology 05/2014; 100(2). DOI:10.1007/s12185-014-1597-8 · 1.92 Impact Factor
Show more